| Literature DB >> 29437903 |
Ruixue Chen1, Minghao Chen2, Ya Xiao1, Qiuer Liang1, Yunfei Cai1, Liguo Chen3, Meixia Fang4.
Abstract
In traditional Chinese medicine (TCM), blood stasis syndrome (BSS) is mainly manifested by the increase of blood viscosity, platelet adhesion rate and aggregation, and the change of microcirculation, resulting in vascular endothelial injury. It is an important factor in the development of diabetes mellitus (DM). The aim of the present study was to screen out the potential candidate microRNAs (miRNAs) in DM patients with BSS by high-throughput sequencing (HTS) and bioinformatics analysis. Human umbilical vein endothelial cells (HUVECs) were incubated with 10% human serum to establish models of DM with BSS, DM without BSS (NBS), and normal control (NC). Total RNA of each sample was extracted and sequenced by the Hiseq2000 platform. Differentially expressed miRNAs (DE-miRNAs) were screened between samples and compared with known changes in mRNA abundance. Target genes of miRNAs were predicted by softwares. Gene Ontology (GO) and pathway enrichment analysis of the target genes were conducted. According to the significantly enriched GO annotations and pathways (P-value ≤ 0.001), we selected the key miRNAs of DM with BSS. It showed that the number of DE-miRNAs in BSS was 32 compared with non-blood stasis syndrome (NBS) and NC. The potential candidate miRNAs were chosen from GO annotations in which target genes were significantly enriched (-log10 (P-value) > 5), which included miR-140-5p, miR-210, miR-362-5p, miR-590-3p, and miR-671-3p. The present study screened out the potential candidate miRNAs in DM patients with BSS by HTS and bioinformatics analysis. The miRNAs will be helpful to provide valuable suggestions on clinical studies of DM with BSS at the gene level.Entities:
Keywords: bioinformatics; blood stasis syndrome; diabetes; endothelial cells; microRNA
Mesh:
Substances:
Year: 2018 PMID: 29437903 PMCID: PMC5861324 DOI: 10.1042/BSR20171208
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1Proportion of small RNAs reads by Rfam database.
Summary of sequence statistics of the samples
| Group | Total reads | High quality | Clean reads | Mapped clean reads | Unique reads |
|---|---|---|---|---|---|
| QDBS | 26359269 | 12893670 | 11531953 | 10038161 | 944791 |
| QSBS | 28406778 | 8737699 | 8255960 | 6778666 | 787743 |
| CCBS | 30872981 | 13804320 | 12959680 | 10723503 | 835698 |
| HABS | 29157502 | 10311967 | 9753552 | 7973897 | 801745 |
| NBS | 40339424 | 11231087 | 10768288 | 9211771 | 590405 |
| NC | 17440198 | 15261312 | 6297952 | 3815519 | 253955 |
The DE-miRNAs in BSS, log2 (FC)
| miRNA | BSS vs. NBS (NC) | |||
|---|---|---|---|---|
| QDBS | QSBS | CCBS | HABS | |
| hsa-miR-1292-3p | 4.69 (7.01) | 5.76 (8.07) | 5.92 (8.24) | 4.71 (7.03) |
| hsa-miR-140-5p | 0.28 (2.76) | 0.18 (2.66) | 0.3 (2.78) | 0.14 (2.63) |
| hsa-miR-155-5p | 0.28 (4.48) | 0.41 (4.6) | 0.23 (4.42) | 0.4 (4.6) |
| hsa-miR-18a-5p | 0.12 (2.8) | 0.13 (2.81) | 0.27 (2.95) | 0.11 (2.79) |
| hsa-miR-20a-3p | 0.83 (3.63) | 0.59 (3.38) | 0.57 (3.36) | 0.51 (3.31) |
| hsa-miR-221-3p | 0.17 (2.48) | 0.75 (3.06) | 0.62 (2.93) | 0.15 (2.46) |
| hsa-miR-23a-3p | 0.54 (3.02) | 0.57 (3.05) | 0.35 (2.83) | 0.25 (2.73) |
| hsa-miR-362-5p | 0.3 (2.96) | 0.52 (3.18) | 0.35 (3.01) | 0.17 (2.82) |
| hsa-miR-3679-5p | 1.62 (10.38) | 1.43 (10.19) | 0.9 (9.66) | 1.44 (10.2) |
| hsa-miR-374a-5p | 0.43 (6.45) | 0.64 (6.65) | 0.81 (6.83) | 0.25 (6.27) |
| hsa-miR-374b-5p | 0.6 (3.51) | 1.02 (3.93) | 0.61 (3.52) | 0.39 (3.31) |
| hsa-miR-4423-3p | 2.3 (8.88) | 2.49 (9.07) | 1.66 (8.24) | 2.44 (9.03) |
| hsa-miR-4517 | 1.45 (4.59) | 0.56 (3.7) | 1.23 (4.37) | 0.86 (4) |
| hsa-miR-4521 | 0.83 (7.22) | 0.15 (6.54) | 0.54 (6.93) | 0.43 (6.82) |
| hsa-miR-590-3p | 0.81 (2.89) | 1.17 (3.24) | 1.05 (3.12) | 0.71 (2.79) |
| hsa-miR-7-1-3p | 0.79 (2.53) | 0.41 (2.16) | 0.31 (2.05) | 0.37 (2.12) |
| hsa-miR-96-5p | 0.41 (5.14) | 0.14 (4.87) | 0.53 (5.26) | 0.25 (4.98) |
| hsa-miR-1307-5p | −1.13 (−3.92) | −1.17 (−3.96) | −0.9 (−3.7) | −0.45 (−3.24) |
| hsa-miR-130b-3p | −0.39 (−0.35) | −0.14 (−0.1) | −0.6 (−0.56) | −0.2 (−0.16) |
| hsa-miR-151a-3p | −0.33 (−0.3) | −0.15 (−0.12) | −0.2 (−0.25) | −0.16 (−0.14) |
| hsa-miR-181c-3p | −0.59 (−1.21) | −0.44 (−1.06) | −0.25 (−0.87) | −0.59 (−1.21) |
| hsa-miR-192-5p | −0.38 (−2.75) | −0.34 (−2.71) | −0.16 (−2.53) | −0.15 (−2.51) |
| hsa-miR-196a-3p | −1.06 (−0.97) | −0.68 (−0.59) | −0.87 (−0.78) | −0.54 (−0.45) |
| hsa-miR-210 | −0.54 (−0.3) | −0.81 (−0.57) | −0.77 (−0.53) | −0.42 (−0.18) |
| hsa-miR-22-3p | −0.32 (−1.03) | −0.01 (−0.73) | -0.12 (−0.84) | −0.13 (−0.84) |
| hsa-miR-29b-3p | −0.71 (−0.15) | −0.65 (−0.09) | −0.67 (−0.11) | −0.64 (−0.08) |
| hsa-miR-29c-3p | −0.44 (−4.71) | −0.53 (−4.8) | −0.31 (−4.58) | −0.38 (−4.65) |
| hsa-miR-30a-5p | −0.09 (−1.24) | −0.25 (−1.4) | −0.22 (−1.37) | −0.04 (−1.19) |
| hsa-miR-30e-5p | −0.44 (−3.01) | −0.48 (−3.05) | −0.35 (−2.92) | −0.27 (−2.84) |
| hsa-miR-378c | −0.8 (−1.44) | −0.44 (−1.07) | −0.69 (−1.33) | −0.51 (−1.14) |
| hsa-miR-378d | −0.79 (−1.38) | −0.56 (−1.14) | −0.79 (−1.37) | −0.73 (−1.31) |
| hsa-miR-671-3p | −0.51 (−1.86) | −0.4 (−1.74) | −0.89 (−2.23) | −0.6 (−1.95) |
Figure 2GO enrichment analysis of 111 DE-mRNAs in BSS, compared with NBS and NC.
Figure 3Pathway enrichment analysis of 111 DE-mRNAs in BSS, compared with NBS and NC.
The significantly enriched GO annotations (-log10 (P-value) > 5)
| No. | GO term | −log10 ( | Protein |
|---|---|---|---|
| 1 | Nucleus | 41.69 | SLC2A4RG; PDX1; NIP7; UPF3A; ZNF655; RFC5; TBX2; ZNF576; CINP; JDP2; OSR2; ZNF282 |
| 2 | Protein binding | 31.67 | PDZD4; ARFRP1; PDX1; NIP7; UPF3A; ZNF655; TIMM44; TBX2; CD81; MLPH |
| 3 | Zinc ion binding | 17.24 | SLC2A4RG; ZNF655; ZNF576; MLPH; OSR2; ZNF282 |
| 4 | Cytoplasm | 13.73 | SLC2A4RG; UMODL1; PDZD4; IER2; UPF3A; RABEP2; MLPH |
| 5 | Cytoplasm | 13.73 | SLC2A4RG; UMODL1; PDZD4; IER2; UPF3A; RABEP2; MLPH |
| 6 | Integral to membrane | 12.66 | UMODL1 |
| 7 | Metal ion binding | 12.28 | SLC2A4RG; ZNF655; ZNF576; MLPH; OSR2; ZNF282 |
| 8 | Plasma membrane | 10.74 | UMODL1; GRM5 |
| 9 | Membrane | 10.74 | TIMM44; CD81 |
| 10 | Regulation of transcription, DNA-dependent | 10.66 | SLC2A4RG; ZNF655; ZNF576; JDP2; ZNF282 |
| 11 | Extracellular region | 10.00 | UMODL1; NOG |
| 12 | Transcription | 9.09 | SLC2A4RG; ZNF655; ZNF576; JDP2; ZNF282 |
| 13 | Transcription factor activity | 9.04 | SLC2A4RG; PDX1; TBX2; JDP2 |
| 14 | Sequence-specific DNA binding | 7.6 | PDX1; TBX2; JDP2 |
| 15 | Integral to plasma membrane | 6.99 | GRM5; CD81 |
| 16 | Intracellular | 6.67 | SLC2A4RG; ARFRP1; ZNF655; ZNF576; CAPN6; OSR2; ZNF282 |
| 17 | Nucleotide binding | 6.6 | ARFRP1; UPF3A; TIMM44;RFC5 |
| 18 | DNA binding | 6.19 | ZNF655; ZNF576; ZNF282 |
| 19 | Development | 6.08 | PDX1; TBX2 |
| 20 | Positive regulation of cell proliferation | 5.67 | PDX1; TBX2; CD81; OSR2 |
The potential candidate miRNAs in BSS
| MiRNA | Target gene | Description |
|---|---|---|
| hsa-miR-140-5p | SLC2A4RG | SLC2A4 regulator |
| UMODL1 | Uromodulin-like 1 | |
| hsa-miR-210 | PDZD4 | PDZ domain containing 4 |
| ARFRP1 | ADP-ribosylation factor related protein 1 | |
| NSUN5 | NOL1/NOP2/Sun domain family, member 5 | |
| PDX1 | Pancreatic and duodenal homeobox 1 | |
| GRM5 | Glutamate receptor, metabotropic 5 | |
| UMODL1 | Uromodulin-like 1 | |
| hsa-miR-362-5p | NIP7 | Nuclear import 7 homolog ( |
| IER2 | Immediate early response 2 | |
| UPF3A | UPF3 regulator of nonsense transcripts homolog A | |
| ZNF655 | Zinc finger protein 655 | |
| hsa-miR-590-3p | TIMM44 | Translocase of inner mitochondrial membrane 44 homolog |
| RFC5 | Replication factor C (activator 1) 5, 36.5kDa | |
| TBX2 | T-box 2 | |
| ZNF576 | Zinc finger protein 576 | |
| SLC2A4RG | SLC2A4 regulator | |
| RABEP2 | Rabaptin, RAB GTPase binding effector protein 2 | |
| hsa-miR-671-3p | CAPN6 | Calpain 6 |
| CINP | Cyclin-dependent kinase 2-interacting protein | |
| CD81 | CD81 molecule | |
| MLPH | Melanophilin | |
| JDP2 | Jun dimerization protein 2 | |
| OSR2 | Odd-skipped related 2 ( | |
| ZNF282 | Zinc finger protein 282 | |
| UMODL1 | Uromodulin-like 1 | |
| RABEP2 | Rabaptin, RAB GTPase binding effector protein 2 | |
| NOG | Noggin | |
| ZNF655 | Zinc finger protein 655 |